FamiCord AG / DE000A0BL849

Leipzig, 27 August 2025 – FamiCord AG, Europe's leading cell bank and the third largest worldwide, continued to grow at double-digit rates in the second quarter, extending its growth trend for the tenth consecutive quarter. Furthermore, the development of earnings quality is becoming increasingly dynamic with EBITDA almost doubling year-on-year. Revenue increased by 14.6 percent to €43.6 million in the first half of 2025 compared to the same period last year (H1 2024: €38.0 million). The net total of invoiced services in the end customer business (B2C) rose by 4.4 percent to €37.4 million (H1 2024: €35.9 million), while the share of annually recurring payments increased by 5.5 percent to €11.6 million (H1 2024: €11.0 million). "In the first half of the year, we further consolidated our turnaround, continued our growth course, and set important strategic milestones for the future – despite persistently challenging market conditions," explains Jakub Baran, CEO of FamiCord AG. "Although the overall economic environment in Europe, particularly in Germany, remains uncertain and birth rates remain low, we were able to achieve significant growth in our core business and further expand our market-leading position in the field of umbilical cord blood banking in Europe." The positive business trends in the Eastern European markets continued, and demand for the company's services remained strong. The same applies to the GCC region. In contrast, the picture in the Central European markets remained mixed. While some markets are showing satisfactory development overall, others still lack growth momentum. On a positive note, however, demand continued to stabilize and further market contraction was prevented through targeted customer outreach. In some Southern European markets, it has not yet been possible to break the negative market trend. A noticeable improvement in the demand situation in key markets will therefore remain a clear focus for the company in the coming quarters. The key figures for business development are as follows:

	IFRS, in EUR ‘000	Q2	Q2	H1	H1
		2025	2024	2025	2024	?
	Group revenue	21,490	19,473	43,577	38,029	14.6%
	Gross profit	8,938	7,422	17,854	14,610	22.2%
	EBITDA (cont. operations)	1,838	1,703	4,977	3,653	36.2%
	EBITDA margin [%]	8.6	8.7	11.4	9.6	1.8 PP
	EBIT	-245	- 556	776	- 817	194.9%
	Result for the period (cont. operations)	802	- 1,229	550	- 1,443	138.1%
	Result for the period (discont. operations)	- 225	- 516	- 633	- 924	31.5%
	Earnings per share [in EUR] (cont. operations)	0.05	- 0.07	0.03	-0.08	137.7%
	Operating cash flow			248	4,315	- 94.3%
	Cash & cash equivalents (vs. 31 Dec. 2024)			10,783	16,823	- 35.9%

Earnings before interest, taxes, depreciation, and amortization (EBITDA) from continuing operations rose again disproportionately by 36.2 percent to €5.0 million (H1 2024: €3.7 million), mainly due to the strong contribution of the core business and a continued focus on cost optimization. The EBITDA margin improved to 11.4 percent (H1 2024: 9.6 percent). Net income from continuing operations returned to positive territory at €0.55 million (H1 2024: €-1.44 million), marking an important milestone in the Group's realignment toward financial strength. Contrary to the positive general business trend, operating cash flow developed negatively and, at €0.25 million, was significantly lower than in the previous year (H1 2024: €4.3 million). The reason for this development continues to be, on the one hand, high demand for annual payment contracts in new customer business. Although these strengthen the long-term basis for business development, they have a negative impact on cash flow development in the short term. In addition, a high one-time tax refund in the previous year continues to distort the cash flow comparison in 2025. Cash and cash equivalents amounted to €10.8 million (31 December 2024: €16.8 million), a decline of 35.9 percent, which was significantly influenced by a combined transaction in Slovakia and the Czech Republic. The shareholdings of the subsidiaries in these markets were increased from 26 percent to 95 percent. This enables full consolidation of these important markets at Group level and reflects the clear focus on the company's core business. The transaction was financed entirely from cash and cash equivalents, with a smaller second payment planned for the end of 2025. A central strategic step in the second quarter was the Management Board’s decision to not further prioritize development of own CAR-T cell therapies but to reemphasize the core potential and promotion of stem cell therapies. The Management Board believes FamiCordTx will continue its activity being supported by current minority shareholders and potential further new investors. This ultimately means, that FamiCordTx as an entity and CAR-T as business operations as such will no longer be included in the Group EBITDA, which leads to a restatement retrospectively with effect starting from 1 January 2024. For the second half of 2025, the Management Board expects the core business to continue to develop positively. The experience of recent quarters underscores the importance of targeted, regionally differentiated sales management and strict cost control. Following the extensive expansion of the technical infrastructure and the successful rebranding to FamiCord, profitability and sustainable, profitable growth are the focus of all future activities. The Management Board is convinced that a renewed focus on the core business, combined with profit-oriented growth management and operational excellence, will restore FamiCord to its former profitability and financial strength. The Management Board therefore reaffirms its outlook for the 2025 financial year, although it anticipates continued consumer uncertainty due to US politics and geopolitical upheavals. The Management Board of FamiCord AG will present developments in the current half-year to institutional investors, analysts, and members of the press today between 11:00 a.m. and 11:30 a.m. as part of the Hamburger Investoren Tage. The presentation can be followed live via the following web link: https://www.appairtime.com/de/event/675aaf5b-0fd8-4952-8166-4eb273dfec3e Afterwards, the Management Board and Investor Relations will be available to conference participants in several 1on1 meetings. Further information on FamiCord and its affiliated subsidiaries can be found at www.famicord.com. Contact: 
FamiCord AG
Ingo Middelmenne
Investor Relations
Phone: +49 (0341) 48792 40
Email: ingo.middelmenne@famicord.com
  Company profile
FamiCord (formerly Vita 34) was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since offered the collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service provider for cryopreservation. The donor's own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from about 50 countries have already provided for the health of their families with about one million units of stored biological material at FamiCord. Furthermore, the Company is active in the area of CDMO.